Protection against MUC1 expressing mouse tumours by intra-muscular injection of MUC1 cDNA requires functional CD8+ and CD4+ T cells but does not require the MUC1 tandem repeat domain

International Journal of Cancer

Volumn 109, Issue 5, 2004, Pages 691-697

  Plunkett, Tim ^a   Graham, Rosalind ^a   Correa, Isobel ^a   Sewell, Robert ^a   Miles, David ^a   Burchell, Joy ^a   Taylor Papadimitriou, Joyce ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

CDNA vaccination; Immunotherapy; Lamp1; MUC1; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; DNA VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MUCIN 1; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SPLEEN CELL; STRAIN DIFFERENCE; T LYMPHOCYTE ACTIVATION; TANDEM REPEAT; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD; CA-15-3 ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; INJECTIONS, INTRAMUSCULAR; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; TANDEM REPEAT SEQUENCES; TIME FACTORS;

EID: 1642632498     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20040     Document Type: Article

References (38)

1. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989;43: 1072-6.
2. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
3. Plunkett TA, Correa I, Miles DW, Taylor-Papadimitriou J. Breast cancer and the immune system: opportunities and pitfalls. J Mammary Gland Biol Neoplasia 2001;6:467-75.
4. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A phase 1 trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996;63:298-304.
5. Musselli C, Livingston PO, Ragupathi G. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J Cancer Res Clin Oncol 2001;127:R20-6.
6. Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997;100:2783-92.
7. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF. CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol 1995;155:5089-94.
8. Heukamp LC, van Hall T, Ossendorp F, Burchell JM, Melief CJ, Taylor-Papadimitriou J, Offringa R. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 2002;25:46-56.
9. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766-74.
10. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17.
11. -/- × β2 microglobulin (β2m) null mice transgenic for a chimeric HLA-A2.1/ Db-β2 microglobulin single chain. Int J Cancer 2000;85:391-7.
12. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 2001;91:385-92.
13. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Obemiedermayr M, Schirrmacher V, Umansky V. Therapy of human tumors in NOD/ SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8.
14. Graham R, Burchell J, Beverley P, Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic tumour cells. Int J Cancer 1996;65:664-70.
15. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani E-N, Wilson D. Molecular cloning and expression of a human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-93.
16. Pemberton LF, Rughetti A, Taylor-Papadimitriou J, Gendler SJ. The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells. J Biol Chem 1996;271:2332-40.
17. Lalani EN, Berdichevsky F, Boshell M, Shearer M, Wilson D, Stauss H, Gendler SJ, Taylor-Papadimitriou J. Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J Biol Chem 1991;266:15420-6.
18. Guarnieri F, Arterburn L, Penno M, Cha Y, August J. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1. J Biol Chem 1993; 268:1941-6.
19. Plunkett TA. Studies of the murine and human immune response to the tumour-associated antigen MUC1. PhD Thesis 2003. University of London.
20. Martins L, Lau L, Asano M, Ahmed R. DNA vaccination against persistent viral infection. J Virol 1995;69:2574-82.
21. Yokoyama M, Zhang J, Whitton J. DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J Virol 1995;69:2684-88.
22. Zarozinski C, Fynan E, Selin L, Robinson H, Welsh R. CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J Immunol 1995;154:4010-17.
23. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 1998;393:478-80.
24. + T-helper and a T-killer cell. Nature 1998;393:474-8.
25. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-3.
26. Wu T-C, Guarnieri F, Staveley-O'Carroll K, Viscidi R, Levitsky H, Hedrick L, Cho K, August J, Pardoll D. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671-75.
27. Bernard H, Oltersdorf T, Seedorf K. Expression of the HPV type 18 E7 gene by a cassette-vector system for the transcription and translation of open reading frames in eukaryotic cells. EMBO J 1987;6: 133-8.
28. Altschuler Y, Kinlough CL, Poland PA, Bruns JB, Apodaca G, Weisz OA, Hughey RP. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell 2000;11:819-31.
29. Litvinov SV, Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem 1993;268:21364-71.
30. Ji H, Wang T-L, Chen C, Pai S, Hung C-F, Lin K-Y, Kurman R, Pardoll D, Wu T-C. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the anti-tumour immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumours. Hum Gene Ther 1999;10:2727-40.
31. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164:4635-40.
32. Rodriguez F, Zhang J, Whitton LJ. DNA Immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997; 71:8497-503.
33. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Ann Rev Immunol 1995;13:151-77.
34. Constant SL, Lee SL, Bottomly K. Site of antigen delivery can influence T cell priming: pulmonary environment promotes preferential Th2 type priming. Eur J Immunol 2000;30:840-47.
35. Apostolopoulos V, Haurum J, McKenzie IFC. MUC1 peptide epitopes associated with 5 different H2 class molecules. Eur J Immunol 1997; 27:2579-85.
36. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000;23:570-80.
37. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21.
38. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L Jr, Hanisch FG, Finn OJ. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002;196:1435-46.